Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of Ixekizumab Treatment on Itch and Psoriasis Area and Severity Index in Patients with Moderate-to-Severe Plaque Psoriasis: An Integrated Analysis of Two Phase III Randomized Studies.
Yosipovitch G, Reich A, Steinhoff M, Beselin A, Kent T, Dossenbach M, Berggren L, Henneges C, Luger T. Yosipovitch G, et al. Among authors: dossenbach m. Dermatol Ther (Heidelb). 2018 Dec;8(4):621-637. doi: 10.1007/s13555-018-0267-9. Epub 2018 Nov 21. Dermatol Ther (Heidelb). 2018. PMID: 30465321 Free PMC article. Review.
A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatment.
Reich K, Augustin M, Thaçi D, Pinter A, Leutz A, Henneges C, Schneider E, Schacht A, Dossenbach M, Mrowietz U. Reich K, et al. Among authors: dossenbach m. Br J Dermatol. 2020 Apr;182(4):869-879. doi: 10.1111/bjd.18384. Epub 2019 Nov 19. Br J Dermatol. 2020. PMID: 31376153 Free PMC article. Clinical Trial.
Absolute and Relative Psoriasis Area and Severity Indices (PASI) for Comparison of the Efficacy of Ixekizumab to Etanercept and Placebo in Patients with Moderate-to-severe Plaque Psoriasis: An Integrated Analysis of UNCOVER-2 and UNCOVER-3 Outcomes.
Puig L, Dossenbach M, Berggren L, Ljungberg A, Zachariae C. Puig L, et al. Among authors: dossenbach m. Acta Derm Venereol. 2019 Oct 1;99(11):971-977. doi: 10.2340/00015555-3245. Acta Derm Venereol. 2019. PMID: 31240322 Free article.
Network meta-analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion method.
Mrowietz U, Warren RB, Leonardi CL, Saure D, Petto H, Hartz S, Dossenbach M, Reich K. Mrowietz U, et al. Among authors: dossenbach m. J Eur Acad Dermatol Venereol. 2021 May;35(5):1161-1175. doi: 10.1111/jdv.17130. Epub 2021 Feb 15. J Eur Acad Dermatol Venereol. 2021. PMID: 33480102 Free PMC article.
Greater cumulative benefits from ixekizumab versus ustekinumab treatment over 52 weeks for patients with moderate-to-severe psoriasis in a randomized, double-blinded phase 3b clinical trial.
Blauvelt A, Lomaga M, Burge R, Zhu B, Shen W, Shrom D, Dossenbach M, Pinter A. Blauvelt A, et al. Among authors: dossenbach m. J Dermatolog Treat. 2020 Mar;31(2):141-146. doi: 10.1080/09546634.2019.1587146. Epub 2019 Mar 18. J Dermatolog Treat. 2020. PMID: 30799638 Clinical Trial.
47 results